marketinsights

Breaking News: Bionomics’ BNC210 Shows Promising Results in Battling Social Anxiety Disorder – Let’s Prevail Together!

Welcome to the Bionomics Blog! Exploring the Latest Updates on BNC210 for Social Anxiety Disorder Hey there, fellow anxiety warriors! Today, we’re diving into the recent topline results of Bionomics’ PREVAIL Phase 2 study of BNC210 in Social Anxiety Disorder (SAD). Exciting, right? Well, let’s get into it! BNC210 for Treatment of Social Anxiety Disorder…

Read More

Attention Wine Lovers: Vintage Wine Estates Inc. Faces Class Action Lawsuit – What You Need to Know

Vintage Wine Alert: Class Action Lawsuit Filed by Bragar Eagel & Squire, P.C. What’s Happening with Vintage Wine Estates, Inc.? It’s not every day that a class action lawsuit gets filed against a wine company, but that’s exactly what’s going on with Vintage Wine Estates, Inc. The nationally recognized stockholder rights law firm, Bragar Eagel…

Read More

Breaking News: Chalice Brands Releases Exciting Preliminary Fiscal Year End Results and Operational Update for 2021!

Breaking News: Chalice Brands Releases Exciting Preliminary Fiscal Year End Results and Operational Update for 2021! Description: PORTLAND, Ore., Dec. 16, 2022 (GLOBE NEWSWIRE) — Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (the “Company” or “Chalice Brands”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, today announces select preliminary unaudited…

Read More

Unlocking New Revenue: Vivos Therapeutics’ Strategic Partnership with Nexus Dental Systems for Streamlined Medical Billing

New Collaboration to Increase Payer Reimbursements and Patient Access LITTLETON, Colo., Dec. 15, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today announced the creation of a new strategic collaboration with Nexus Dental Systems (“Nexus”), which Vivos expects to generate new revenues starting immediately. Vivos and Nexus believe their alliance…

Read More

Keros Therapeutics Unveils Exciting Clinical and Preclinical Data at the 64th American Society of Hematology Annual Meeting

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-… Keros Therapeutics Hosts Conference Call and Webcast Keros Therapeutics will be hosting a conference call and webcast today, December 12, 2022, at 4:01 p.m. ET. The event will provide an opportunity for investors, analysts, and the general public to learn more about the latest clinical…

Read More

ALX Oncology Unveils Promising Results from Aspen-05 Study: Evorpacept in Combination with Azacitidine and Venetoclax Shows Tolerability and Early Efficacy in Acute Myeloid Leukemia Patients

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax Antileukemic Activity Demonstrated ALX Oncology recently announced the initial data from the ASPEN-05 study, showcasing promising antileukemic activity in patients with both relapsed/refractory and newly diagnosed Acute Myeloid Leukemia (AML). No Observations of Cytopenias or Maximum Tolerated Dose The…

Read More